Loading
NASDAQTechnologySoftware - Application
Latest quote
$8.30
−$0.10 · -1.19%
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Previous close
$8.30
−$0.10 · -1.19%
Regular session · ET · Market data may be delayed.
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Day range
Current $8.30
52-week range
Current $8.30
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
48
Mixed
Risk
43
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Day range
Current $8.30
52-week range
Current $8.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 257.07M EUR | 266.77M EUR | 256.13M EUR | 232.02M EUR | 205.45M EUR |
| Cost of goods sold | 110.16M EUR | 115.94M EUR | 111M EUR | 103.26M EUR | 87.28M EUR |
| Gross profit | 146.91M EUR | 150.83M EUR | 145.13M EUR | 128.77M EUR | 118.17M EUR |
| Research and development | 44.27M EUR | 44.4M EUR | 38.1M EUR | 37.57M EUR | 26.89M EUR |
| Selling, general, and administrative | 96.32M EUR | 101.22M EUR | 94.89M EUR | 93.02M EUR | 77.59M EUR |
| Operating expenses | 141.97M EUR | 141.39M EUR | 139.51M EUR | 131.64M EUR | 105.96M EUR |
| Interest income | 3.81M EUR | 4.25M EUR | 4.45M EUR | 1.4M EUR | 777.74K EUR |
| Interest expense | 5.39M EUR | 1.65M EUR | 2.09M EUR | 2.92M EUR | 3.36M EUR |
| Depreciation and amortization | 20.85M EUR | 21.76M EUR | 21.57M EUR | 22.57M EUR | 20.55M EUR |
| Operating income | 4.94M EUR | 9.43M EUR | 5.62M EUR | −2.87M EUR | 12.22M EUR |
| Net income | 7.41M EUR | 13.44M EUR | 6.72M EUR | −2.12M EUR | 13.15M EUR |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
20.48% upsideFunds reporting this stock among their holdings, ordered by reported position size.
The 3D Printing ETFPRNT2.87M4.64%58.7M USD0.66%$25.50+0.80%
Pacer BlueStar Engineering the Future ETFBULD328.78K2.21%14.88M USD0.49%$37.238+0.94%
ActivePassive International Equity ETFAPIE254.74K0.02%1.14B USD0.45%$38.56+0.65%
State Street SPDR S&P International Small Cap ETFGWX216.35K0.02%907.87M USD0.40%$45.56+0.93%
State Street SPDR Portfolio Developed World ex-US ETFSPDW83.35K0.00%40.46B USD0.03%$49.98+0.64%The 3D Printing ETFPRNTPacer BlueStar Engineering the Future ETFBULDActivePassive International Equity ETFAPIEState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Developed World ex-US ETFSPDWAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
